GlassScriptPhysician profile
Sherman Chu
NPI 1760988927
$3,677.66
in general payments reported to CMS, 2019-2025
17 companies · $903 in 2025
The $903 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $930 · 2023: $863 · 2024: $982 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.87 | 2022-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $474.19 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $464.77 | 2022-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $402.01 | 2022-2025 | Sotyktu |
| Organon LLC | $287.47 | 2025 | Vtama |
| Amgen INC. | $286.05 | 2022-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $265.36 | 2024-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.82 | 2022-2024 | Spevigo |
| Biohaven Pharmaceutical Holding Company LTD. | $123.57 | 2022 | |
| Krystal Biotech INC | $122.49 | 2023 | Vyjuvek |
| Janssen Scientific Affairs, LLC | $119.47 | 2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $60.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $30.55 | 2022 | |
| Lilly USA, LLC | $27.11 | 2025 | Ebglyss |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.49 | 2025 | |
| Csl Behring | $20.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherman Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.